Abstract
During the last two decades, protein kinases have emerged as a major target for cancer therapy and a large number of selective kinase inhibitors have been developed as potential anticancer drugs. To avoid unpredictable toxic effects, researchers usually aim at designing highly selective inhibitors. But since the formation and progression of a tumor has to be considered as a multifactorial process, which is dependent on different signalling pathways, it seems reasonable to establish anticancer therapies that target several kinases associated with tumor growth. In general, this can be achieved by two different strategies, either by concomitantly using a combination of a set of selective kinase inhibitors or by administering a single agent, which simultaneously inhibits several kinases, a so called multi-kinase inhibitor. In this review, benefits and obstacles of both strategies are discussed. An overview over recently approved and newly upcoming multi-kinase inhibitors is given.
Keywords: Multiple targeted, kinase inhibitor, development
Mini-Reviews in Medicinal Chemistry
Title: Recent Advances in the Development of Multi-Kinase Inhibitors
Volume: 8 Issue: 13
Author(s): Martin Krug and Andreas Hilgeroth
Affiliation:
Keywords: Multiple targeted, kinase inhibitor, development
Abstract: During the last two decades, protein kinases have emerged as a major target for cancer therapy and a large number of selective kinase inhibitors have been developed as potential anticancer drugs. To avoid unpredictable toxic effects, researchers usually aim at designing highly selective inhibitors. But since the formation and progression of a tumor has to be considered as a multifactorial process, which is dependent on different signalling pathways, it seems reasonable to establish anticancer therapies that target several kinases associated with tumor growth. In general, this can be achieved by two different strategies, either by concomitantly using a combination of a set of selective kinase inhibitors or by administering a single agent, which simultaneously inhibits several kinases, a so called multi-kinase inhibitor. In this review, benefits and obstacles of both strategies are discussed. An overview over recently approved and newly upcoming multi-kinase inhibitors is given.
Export Options
About this article
Cite this article as:
Krug Martin and Hilgeroth Andreas, Recent Advances in the Development of Multi-Kinase Inhibitors, Mini-Reviews in Medicinal Chemistry 2008; 8 (13) . https://dx.doi.org/10.2174/138955708786369591
DOI https://dx.doi.org/10.2174/138955708786369591 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Berberine Exhibits Antitumor Effects in Human Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Dysfunction of Mitochondrial ATP Production As a Target for Personalized Cancer Therapy
Current Pharmacogenomics and Personalized Medicine Design Strategies, Structures and Molecular Interactions of Small Molecule Src Inhibitors
Anti-Cancer Agents in Medicinal Chemistry A Systems Biology Road Map for the Discovery of Drugs Targeting Cancer Cell Metabolism
Current Pharmaceutical Design Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition
Current Genomics Metallothioneins and Cancer
Current Protein & Peptide Science Mapping the High Throughput SEREX Technology Screening for Novel Tumor Antigens
Combinatorial Chemistry & High Throughput Screening Artificial Intelligence in Pharmaceutical Field - A Critical Review
Current Drug Delivery Phospho-eIF4E: A New Target for Acute Myeloid Leukemia
Current Protein & Peptide Science mTOR Inhibitors: Facing New Challenges Ahead
Current Medicinal Chemistry HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Anesthetic Pharmacology for Kidney Transplantation
Current Clinical Pharmacology Multidisciplinary Cancer Therapy with Telomerase-Specific Oncolytic Adenovirus
Current Cancer Therapy Reviews Effects of Iron Chelation in Osteosarcoma
Current Cancer Drug Targets Current Status and Future Perspectives of Chemoprevention in Head and Neck Cancer
Current Cancer Drug Targets Nanoparticle Albumin - Bound (NAB) Technology is a Promising Method for Anti-Cancer Drug Delivery
Recent Patents on Anti-Cancer Drug Discovery Influence of Polyphenol-plasma Protein Interaction on the Antioxidant Properties of Polyphenols
Current Drug Metabolism Prodrugs in Genetic Chemoradiotherapy
Current Pharmaceutical Design Towards Understanding the Role of Cancer-Associated Inflammation in Chemoresistance
Current Pharmaceutical Design Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis
Current Stem Cell Research & Therapy